SpringWorks Completes an Enrollment of Mirdametinib in P-IIb ReNeu Trial for the Treatment of NF1-Associated Plexiform Neurofibromas
- The company has completed enrolment in the P-IIb ReNeu trial to evaluate mirdametinib in 50 adults & ~50 pediatric patients aged 2yrs. with NF1-associated plexiform neurofibromas (NF1-PN)
- The 1EPs of the trial is ORR with ≥ 20% reduction in target tumor volume as measured by MRI & assessed by BICR while 2EPs include safety, tolerability, DoR & changes from baseline in PROs. As of Mar 23, 2021 cutoff date, 50% of patients had achieved an ORR as assessed by BICR, 80% remained on study & median time on treatment was ~12mos.
- Mirdametinib is an oral, allosteric small molecule MEK inhibitor & has received ODD from the US FDA & EC for NF1 & FTD from the US FDA for NF1-PN patients aged ≥2yrs.
Ref: Globenewswire | Image: SpringWorks
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at email@example.com